Published on April 17, 2026 by Alexis Behra
Sector Summary: RNA & Nanoparticular vectorisation
In 2025, France BioLead brought together over a hundred academic and industry experts to identify high-value R&D priorities, key technological bottlenecks, and leading French stakeholders.
Co-organized with the network of integrators in biomanufacturing & biotherapies (RIBB) and the PEPR Biotherapies program, these meetings were structured by biomedicine family.
This summary focuses on RNA and nanoparticules vectorisation. It outlines the technological challenges by therapy type and manufacturing process, highlights priority R&D areas, and maps key French players in the field.
These summaries will be updated periodically — we welcome your feedback.
